» Articles » PMID: 38136564

Adipokines and Bacterial Metabolites: A Pivotal Molecular Bridge Linking Obesity and Gut Microbiota Dysbiosis to Target

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Dec 23
PMID 38136564
Authors
Affiliations
Soon will be listed here.
Abstract

Adipokines are essential mediators produced by adipose tissue and exert multiple biological functions. In particular, adiponectin, leptin, resistin, IL-6, MCP-1 and PAI-1 play specific roles in the crosstalk between adipose tissue and other organs involved in metabolic, immune and vascular health. During obesity, adipokine imbalance occurs and leads to a low-grade pro-inflammatory status, promoting insulin resistance-related diabetes and its vascular complications. A causal link between obesity and gut microbiota dysbiosis has been demonstrated. The deregulation of gut bacteria communities characterizing this dysbiosis influences the synthesis of bacterial substances including lipopolysaccharides and specific metabolites, generated via the degradation of dietary components, such as short-chain fatty acids, trimethylamine metabolized into trimethylamine-oxide in the liver and indole derivatives. Emerging evidence suggests that these bacterial metabolites modulate signaling pathways involved in adipokine production and action. This review summarizes the current knowledge about the molecular links between gut bacteria-derived metabolites and adipokine imbalance in obesity, and emphasizes their roles in key pathological mechanisms related to oxidative stress, inflammation, insulin resistance and vascular disorder. Given this interaction between adipokines and bacterial metabolites, the review highlights their relevance (i) as complementary clinical biomarkers to better explore the metabolic, inflammatory and vascular complications during obesity and gut microbiota dysbiosis, and (ii) as targets for new antioxidant, anti-inflammatory and prebiotic triple action strategies.

Citing Articles

Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.

Linder L Integr Med (Encinitas). 2025; 24(1):26-30.

PMID: 39896831 PMC: 11778319.


Therapeutic Potential of Dimethyl Fumarate for the Treatment of High-Fat/High-Sucrose Diet-Induced Obesity.

Valenca H, Mota E, Silva A, Figueiredo-Junior A, Verdini F, Romana-Souza B Antioxidants (Basel). 2025; 13(12.

PMID: 39765824 PMC: 11673011. DOI: 10.3390/antiox13121496.


Probiotic, Postbiotic, and Paraprobiotic Effects of as a Modulator of Obesity-Associated Factors.

Lopez-Almada G, Mejia-Leon M, Salazar-Lopez N Foods. 2024; 13(22).

PMID: 39593945 PMC: 11592899. DOI: 10.3390/foods13223529.


Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome.

Corona-Meraz F, Vazquez-Del Mercado M, Sandoval-Garcia F, Robles-De Anda J, Tovar-Cuevas A, Rosales-Gomez R J Clin Med. 2024; 13(7).

PMID: 38610754 PMC: 11012563. DOI: 10.3390/jcm13071988.

References
1.
Su K, Li Y, Zhang D, Yuan J, Zhang C, Liu Y . Relation of Circulating Resistin to Insulin Resistance in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis. Front Physiol. 2019; 10:1399. PMC: 6877503. DOI: 10.3389/fphys.2019.01399. View

2.
Cinti S . Adipose Organ Development and Remodeling. Compr Physiol. 2018; 8(4):1357-1431. DOI: 10.1002/cphy.c170042. View

3.
Mehta N, McGillicuddy F, Anderson P, Hinkle C, Shah R, Pruscino L . Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. 2009; 59(1):172-81. PMC: 2797919. DOI: 10.2337/db09-0367. View

4.
Yuan H, Wang W, Chen D, Zhu X, Meng L . Effects of a treatment with Se-rich rice flour high in resistant starch on enteric dysbiosis and chronic inflammation in diabetic ICR mice. J Sci Food Agric. 2016; 97(7):2068-2074. DOI: 10.1002/jsfa.8011. View

5.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View